Astria Therapeutics to Present at Upcoming Global Angioedema Forum
Astria Therapeutics (Nasdaq:ATXS), a biopharmaceutical company focused on allergic and immunologic diseases, announced that leading HAE experts will present two posters at the Global Angioedema Forum (GAF) in Copenhagen, Denmark on October 4-5, 2024.
Dr. Aleena Banerji, Associate Professor of Medicine at Harvard Medical School, will present on the ALPHA-SOLAR trial of navenibart (STAR-0215) for HAE in an encore poster titled “Rationale and Design of the ALPHA-SOLAR Clinical Trial of STAR-0215” on October 4 at 6:00pm CEST.
Dr. William Lumry, Clinical Professor of Internal Medicine at the University of Texas Health Science Center, will present results from the Phase 1b/2 trial of navenibart (STAR-0215) in an encore poster titled “ALPHA-STAR, a Phase 1b/2 Clinical Trial of Single and Multiple Doses of STAR-0215 in Patients with Hereditary Angioedema: Initial Safety and Efficacy Outcomes” during a session titled “Emerging Treatment Options” on October 5 at 9:30am CEST.
Astria Therapeutics (Nasdaq:ATXS), una compagnia biofarmaceutica focalizzata sulle malattie allergiche e immunologiche, ha annunciato che esperti di HAE presenteranno due poster al Global Angioedema Forum (GAF) a Copenaghen, Danimarca, il 4-5 ottobre 2024.
La Dott.ssa Aleena Banerji, Professoressa Associata di Medicina presso la Harvard Medical School, presenterà il trial ALPHA-SOLAR di navenibart (STAR-0215) con un poster di replica intitolato “Razionale e Progetto del Trial Clinico ALPHA-SOLAR di STAR-0215” il 4 ottobre alle 18:00 CEST.
Il Dott. William Lumry, Professore Clinico di Medicina Interna presso l'Università del Texas Health Science Center, presenterà i risultati del trial di Fase 1b/2 di navenibart (STAR-0215) in un poster di replica intitolato “ALPHA-STAR, un Trial Clinico di Fase 1b/2 di Dosi Singole e Multiple di STAR-0215 in Pazienti con Angioedema Ereditario: Risultati Iniziali di Sicurezza ed Efficacia” durante una sessione intitolata “Opzioni di Trattamento Emergenti” il 5 ottobre alle 9:30 CEST.
Astria Therapeutics (Nasdaq:ATXS), una compañía biofarmacéutica centrada en enfermedades alérgicas e inmunológicas, anunció que destacados expertos en HAE presentarán dos carteles en el Global Angioedema Forum (GAF) en Copenhague, Dinamarca, los 4 y 5 de octubre de 2024.
La Dra. Aleena Banerji, Profesora Asociada de Medicina en la Harvard Medical School, presentará el ensayo ALPHA-SOLAR de navenibart (STAR-0215) en un cartel de repetición titulado “Razonamiento y Diseño del Ensayo Clínico ALPHA-SOLAR de STAR-0215” el 4 de octubre a las 18:00 CEST.
El Dr. William Lumry, Profesor Clínico de Medicina Interna en el Centro de Ciencias de la Salud de la Universidad de Texas, presentará los resultados del ensayo de Fase 1b/2 de navenibart (STAR-0215) en un cartel de repetición titulado “ALPHA-STAR, un Ensayo Clínico de Fase 1b/2 de Dosis Únicas y Múltiples de STAR-0215 en Pacientes con Angioedema Hereditario: Resultados Iniciales de Seguridad y Eficacia” durante una sesión titulada “Opciones de Tratamiento Emergentes” el 5 de octubre a las 9:30 CEST.
Astria Therapeutics (Nasdaq:ATXS)는 알레르기 및 면역 질환에 중점을 둔 생명공학 회사로, 덴마크 코펜하겐에서 2024년 10월 4-5일에 열리는 Global Angioedema Forum (GAF)에서 HAE 전문가들이 두 개의 포스터를 발표할 것이라고 발표했습니다.
하버드 의대의 의학 부교수인 Aleena Banerji 박사는 HAE를 위한 navenibart (STAR-0215)의 ALPHA-SOLAR 시험에 대해 “STAR-0215의 ALPHA-SOLAR 임상 시험의 근거 및 디자인”이라는 제목의 반복 포스터를 10월 4일 오후 6:00 CEST에 발표할 예정입니다.
텍사스 대학교 건강 과학 센터의 내과 임상 교수인 William Lumry 박사는 “유전성 혈관부종 환자에 대한 STAR-0215의 단일 및 다회 투여에 대한 1b/2상 ALPHA-STAR 임상 시험: 초기 안전성 및 유효성 결과”라는 제목으로 navenibart (STAR-0215)의 1b/2상 시험 결과를 발표합니다. 이 발표는 10월 5일 오전 9:30 CEST에 “신흥 치료 옵션”이라는 세션에서 진행됩니다.
Astria Therapeutics (Nasdaq:ATXS), une entreprise biopharmaceutique spécialisée dans les maladies allergiques et immunologiques, a annoncé que des experts de premier plan sur l'HAE présenteront deux affiches lors du Global Angioedema Forum (GAF) à Copenhague, au Danemark, les 4 et 5 octobre 2024.
Le Dr Aleena Banerji, professeur associé de médecine à la Harvard Medical School, présentera l'essai ALPHA-SOLAR de navenibart (STAR-0215) dans une affiche d'encore intitulée “Raisonnement et Conception de l'Essai Clinique ALPHA-SOLAR de STAR-0215” le 4 octobre à 18h00 CEST.
Le Dr William Lumry, professeur clinique de médecine interne au Centre de sciences de la santé de l'Université du Texas, présentera les résultats de l'essai de Phase 1b/2 de navenibart (STAR-0215) dans une affiche d'encore intitulée “ALPHA-STAR, un Essai Clinique de Phase 1b/2 avec des Doses Uniques et Multiples de STAR-0215 chez des Patients souffrant d'Angioedème Héréditaire : Résultats Initiaux de Sécurité et d'Efficacité” lors d'une session intitulée “Options de Traitement Émergentes” le 5 octobre à 9h30 CEST.
Astria Therapeutics (Nasdaq:ATXS), ein biopharmazeutisches Unternehmen, das sich auf allergische und immunologische Erkrankungen konzentriert, gab bekannt, dass führende HAE-Experten zwei Poster beim Global Angioedema Forum (GAF) in Kopenhagen, Dänemark, am 4.-5. Oktober 2024 präsentieren werden.
Dr. Aleena Banerji, außerordentliche Professorin für Medizin an der Harvard Medical School, wird am 4. Oktober um 18:00 Uhr CEST ein Encore-Poster mit dem Titel “Rationale und Design der ALPHA-SOLAR-Studie von STAR-0215” über die ALPHA-SOLAR-Studie zu navenibart (STAR-0215) präsentieren.
Dr. William Lumry, klinischer Professor für Innere Medizin am University of Texas Health Science Center, wird Ergebnisse aus der Phase 1b/2-Studie zu navenibart (STAR-0215) in einem Encore-Poster mit dem Titel “ALPHA-STAR, eine Phase 1b/2-Studie zu Einzel- und Mehrfachdosen von STAR-0215 bei Patienten mit hereditärem Angioödemen: Erste Sicherheits- und Wirksamkeitsdaten” vorstellen, und zwar während einer Sitzung mit dem Titel “Neu auftretende Behandlungsoptionen” am 5. Oktober um 9:30 Uhr CEST.
- None.
- None.
- Dr. Aleena Banerji, M.D., Associate Professor of Medicine at Harvard Medical School and Clinical Director of the Allergy and Immunology Unit at Massachusetts General Hospital, will present information on ALPHA-SOLAR, a long-term open-label trial of navenibart (STAR-0215) in people living with HAE, in an encore presentation of a poster titled “Rationale and Design of the ALPHA-SOLAR Clinical Trial of STAR-0215.” The poster session will take place on Friday, October 4 at 6:00pm CEST.
-
Dr. William Lumry, M.D., Clinical Professor of Internal Medicine at the University of Texas Health Science Center at
Dallas , will present results from the Phase 1b/2 trial of navenibart (STAR-0215) in an encore presentation of a poster titled “ALPHA-STAR, a Phase 1b/2 Clinical Trial of Single and Multiple Doses of STAR-0215 in Patients with Hereditary Angioedema: Initial Safety and Efficacy Outcomes.” The presentation will take place during a session titled “Emerging Treatment Options” on Saturday, October 5 at 9:30am CEST.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240927312997/en/
Astria Contact:
Investor Relations and Media:
Elizabeth
investors@astriatx.com
Source: Astria Therapeutics, Inc.
FAQ
What will Astria Therapeutics present at the Global Angioedema Forum in October 2024?
Who will present the ALPHA-SOLAR trial at the Global Angioedema Forum?
When will the ALPHA-STAR trial results be presented at the Global Angioedema Forum?
What is the focus of the ALPHA-STAR clinical trial?
What is the stock symbol for Astria Therapeutics?
